EClinCloud 分析 1,715 条 FDA 检查引用：完整的试验主文件不等于可重建的试验

Across six fiscal years of FDA BIMO inspection data, protocol-compliance, informed-consent and case-history obligations account for 46.2% of citation occurrences — in the company's reading, the clearest signal that inspection readiness should focus on whether the trial record can reconstruct what happened, not on how many documents were stored.

, /PRNewswire/ -- EClinCloud, an AI technology company for clinical research that builds a unified clinical cloud platform and endpoint assessment technology to help improve trial success rates and shorten development cycles, today released an analysis of FDA Bioresearch Monitoring (BIMO) inspection citations spanning fiscal years 2020 through 2025. Across 1,715 citation occurrences in the agency's published inspection-observation workbooks, obligations covering protocol compliance, informed consent and investigator case histories together account for 793 occurrences, or 46.2%. In the company's reading, that concentration makes protocol adherence and trial records the first places FDA inspection readiness should look.

The report is explicit about what those figures measure: cited obligations, not defect rates or inspection outcomes, summed from the frequency fields of FDA's own workbooks (August 2026 snapshot) with every inclusion rule declared. Its central argument follows from that discipline. A trial file is not demonstrated by how many documents it stores: "A trial file becomes useful when an authorized reviewer can connect a decision to the evidence available at the time." Completeness percentages depend entirely on their denominator — in the report's worked illustration, the same hypothetical file scores 95.0% complete against records that are due and applicable, and 76.0% against the raw catalog — and "neither 95% completeness nor a particular sampled pass rate establishes regulatory acceptability." The practical conclusion: read any completeness figure together with its denominator, and treat a high percentage as the starting point for quality review, not its end.

Retention adds a second layer that storage alone cannot solve. Under EU Clinical Trials Regulation Article 58, the trial master file must generally be kept for at least 25 years after the end of a trial, and the retention clock starts from a legal trigger — approval, discontinuation or completion — that itself must be evidenced. As the report puts it, "guessing a date to complete a dashboard can create a false destruction instruction."

In place of document counting, the report proposes — as the company's own framework, not a regulatory checklist — five questions a TMF quality review should answer for any record:

• Applicability and ownership: does this record apply to this trial, and who is responsible for it?
• Identity and integrity: does it belong to the right trial, complete and with verifiable origin?
• Timing and version: does it reflect the version and time of the activity it documents?
• Relationships and decisions: can it be connected to the approvals, actions and decisions it supports?
• Retrieval and preservation: can an authorized user find and understand it throughout the retention period?

"Sponsors tend to manage the TMF as a filing obligation and meet it at closeout — and that is exactly when reconstruction becomes impossible," said Michael Qin, PhD, Founder and Chief Executive Officer of EClinCloud. "An inspector does not ask how many documents you stored. They ask what you knew, when you knew it, and what you did — and the only way to answer is to manage records as part of daily trial execution, with ownership, versions and relationships kept as the trial runs."

This is the role of EClinCloud's eTMF solution, part of the company's unified clinical research platform. Rather than replacing paper binders with electronic folders, it builds the report's five questions into the workflow: AI-suggested document classification confirmed by a person, quality control before filing, real-time visibility into completeness, timeliness and quality, traceability by design, and controlled search, viewing and export — so that at a protocol amendment, a CRO transition or a study closeout, affected documents, approvals and training evidence can be identified and connected from the system of record. Operating alongside EDC, CTMS and eLearning on the company's integrated cloud platform — supporting tightly connected trial workflows that promote timely document filing and management and meet downstream verification and traceability needs — the eTMF keeps filing integrated with trial conduct rather than reconstructed after it. The report itself notes that no system alone guarantees completeness or compliance — outcomes depend on configuration, timeliness, ownership and oversight, which is precisely why the company pairs the software with structured TMF management practice.

The full analysis, including the citation selections, annual results and sensitivity definitions, is available at https://www.eclincloud.com/insights/trial-records-tmf-inspection-citations-2026, part of EClinCloud's Deep Research series at https://www.eclincloud.com/insights. For demonstrations and partnership inquiries, visit https://www.eclincloud.com/demo.

About EClinCloud

EClinCloud (Ningbo) Technology Co., Ltd. builds a unified, AI-driven clinical cloud platform and endpoint assessment technology for global pharmaceutical and research organizations, with a mission to become a global leader in AI-driven clinical research. Its integrated platform — EDC, RTSM, eCOA, IRC, CTMS, eTMF, resource management and eLearning, with embedded AI agents and BI analytics — supports 1,100+ clinical trials, 300+ organizations and 20,000+ users in 10+ countries and regions. EClinCloud is headquartered in Ningbo, China, with offices in Beijing, Shanghai, Chengdu, Shenzhen and New York. More information is available at https://www.eclincloud.com.

Company Contact

EClinCloud — Global Inquiries
EClinCloud (Ningbo) Technology Co., Ltd.
Phone: +86 186 1698 7169
Email: [email protected]
Web: https://www.eclincloud.com/demo

Media Relations

EClinCloud — Press Inquiries
Phone: +1 415 689 1868
Email: [email protected]

Note to Editors

Michael Qin, PhD, is available for interview through the company's contact page. Figures are the company's recomputation of FDA's published BIMO inspection-observation workbooks for FY2020–FY2025 (August 2026 snapshot): 1,715 is the sum of citation-frequency fields across 479 selected rows; the 46.2% combines 21 CFR 312.60 protocol-compliance and informed-consent occurrences (522) with 312.62(b) case-history occurrences (271). The counts describe cited obligations, not defect rates, inspection outcomes or causes; a Form 483 observation is not a final agency determination of a violation, and year-to-year changes are not attributed to any technology. The 95.0%/76.0% completeness contrast is a hypothetical illustration, not observed data. The five-question review framework is the company's editorial proposal. No claim is made that any system guarantees completeness, compliance or inspection outcomes.

SOURCE EClinCloud